David A. Siegel Aldeyra Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 282,900 shares of ALDX stock, worth $1.55 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
282,900
Previous 374,900
24.54%
Holding current value
$1.55 Million
Previous $1.23 Million
23.59%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding ALDX
# of Institutions
107Shares Held
35.2MCall Options Held
153KPut Options Held
83.9K-
Perceptive Advisors LLC New York, NY9.28MShares$50.9 Million0.89% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$30.1 Million12.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.74MShares$20.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$19.9 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.6MShares$8.78 Million0.12% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $320M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...